Skip to main
KLRS

Allovir Inc (KLRS) Stock Forecast & Price Target

Allovir Inc (KLRS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kalaris Therapeutics Inc shows strong potential for positive market performance due to its innovative anti-VEGF drug, TH103, which is designed to provide enhanced retinal retention and prolonged drug activity compared to existing treatments such as Eylea. The company's foundation is supported by impressive preclinical findings, which indicate that TH103 achieves complete inhibition of VEGF-induced endothelial cell proliferation and may translate into significant clinical advantages for patients with prevalent retinal diseases. The overall market for anti-VEGF therapies has demonstrated substantial revenue growth, as seen with competitors exceeding $4 billion in sales, underscoring the considerable opportunities that exist for Kalaris Therapeutics if TH103 capitalizes on its differentiated properties.

Bears say

Kalaris Therapeutics Inc., as a development-stage biotechnology company, has not yet commercialized any products, which raises concerns regarding the establishment of the necessary infrastructure to launch and effectively market TH103. The company is expected to continue incurring substantial net losses until commercialization, with financial risks heightened by potential delays in clinical development, regulatory approvals, and increased costs associated with extended development periods. Additionally, competition from existing and emerging therapies targeting similar indications could hinder market penetration and adversely affect pricing strategies, amplifying the uncertainties surrounding Kalaris's future financial performance.

Allovir Inc (KLRS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allovir Inc (KLRS) Forecast

Analysts have given Allovir Inc (KLRS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Allovir Inc (KLRS) has a Strong Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allovir Inc (KLRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.